[Experience of transcatheter XXXX in the Central Military Hospital].

@entity1 @entity455 @entity548 @entity886 @entity337 @entity810 @entity472 @entity204 @entity385
OBJECTIVE: Transcatheter @entity886 (TAVI) is an alternative treatment for @entity1 with severe @entity472 , inoperable or at high surgical risk. The purpose of this communication is to report the results of the experience of this new technique and compare them with literature. METHODS: Review of 17 @entity1 data with symptomatic severe @entity472 at high surgical risk or inoperable, treated with a transcatheter implantation aortic valve (TAVI) via femoral surgical access with Core Valve (Medtronic, EE.UU.) between September 2013 and July 2014. RESULTS: All @entity1 had severe @entity472 with a mean gradient of 46    14mmHg received CoreValveTM (Medtronic, USA). Half of @entity1 was performed under general anesthesia, the other half with regional and local anesthesia. In-hospital mortality was 11.7% and one @entity204 in follow-up from September 2013 until the time of preparing this report (5.9%).Total mortality at one year follow-up was 17.6%. The technical success rate was 82.4%, with an immediate post-implantation gradient of 5.4    3.4 mmHg. @entity337 I degree was observed in 5 @entity1 (29.4%); 2 @entity1 (11.7%) had @entity337 grade II. Post dilatation was made in 6 @entity1 (35.2%). We did not have any @entity455 . Permanent pacemaker implantation was needed in 6 @entity1 (35.2%). One @entity1 complicated with @entity810 , 2 had in-hospital @entity385 (11.7%), none had need for cardiac surgery; 2 @entity1 had major @entity548 complications that required transfusion. CONCLUSIONS: In @entity1 with high surgical risk or inoperable, TAVI is a treatment option that improves life quality, survival and diminsh the need of hospitalizations. There can be some complications and even @entity204 , so that a proper @entity1 selection and a multidisciplinary team is needed and fundamental for a successful procedure.
